AGY Therapeutics Inc.
This article was originally published in Start Up
AGY Therapeutics is initially focused on studying stroke. It is examining genes the brain switches on in response to damage, on the theory that these gene products might be potential targets for inhibitory therapeutics.
You may also be interested in...
With the limited success of traditional approaches to CNS, scientists are betting that genomics may hold the key to a new generation of drugs that stop disease progression and possibly reverse its impact. At least half a dozen companies focusing mostly on neurogenomics have started up and raised more than $100 million in the past three years. While they use standard genomics tools and follow typical post-genomics business models, they face special challenges due to the complexity of the brain.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.